Artal Group S.A.
Q1 2014 13F-HR Holdings
Net value change ($000)
-25,905
(-0.9%)
New positions
13
Sold out positions
6
Turnover %
8.1%
Sector allocation + QoQ delta (equities-only)
Holdings aggregated across other managers listed in the original SEC filing. View detailed breakdown
Snapshot: Change Analysis
Compared to Q4 2013
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| FURIEX PHARMA INC | 32,920 | 90.0% |
| C | 14,280 | NEW |
| DG | 13,870 | NEW |
| MEAD JOHNSON NUTRITI | 12,471 | NEW |
| DELPHI AUTOMOTIVE PLC | 10,179 | NEW |
| BRFSN | 8,929 | NEW |
| RL | 8,047 | NEW |
| BMRN | 7,670 | 27.3% |
| AUXILIUM PHARMACEUTICALS | 6,278 | 20.2% |
| ALNY | 5,726 | 71.2% |
Top Reduces (Value $000, Stocks/ETFs)
| WTW | -356,202 | -37.6% |
| LEXICON GENETICS INC US$0.001 Common Stock | -17,730 | -3.9% |
| GS | -8,863 | -100.0% |
| XOMA | -8,250 | -61.3% |
| Crown Castle Intl Corp | -7,343 | -100.0% |
| Acorda Therapeutics, Inc. | -7,171 | -35.1% |
| ImmunoGen, Inc. | -4,797 | -19.8% |
| ONIT | -4,159 | -100.0% |
| AVANIR PHARMACEUTICALS INC CL A NEW | -3,417 | -50.8% |
| MTOR | -3,105 | -45.8% |
Instrument mix + QoQ Δ (ex-options)
Derivatives reported exposure ($000):
1,313,065
(47.5% of total reported value)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|